By Stephen Nakrosis 
 

NRx Pharmaceuticals, Inc. on Tuesday said Georgia's prime minister and minister of health gave an emergency use authorization for the company's intravenous Zyesami to treat Covid-19.

The company said its Zyesami, or aviptadil, was given the EUA for the treatment of Critical Covid-19.

The company also said a team of physicians, led by Dr. Javier Perez-Fernandez, "a lead investigator in the Phase 2b/3 clinical trial of intravenous Zyesami," will travel to Georgia to train doctors in that country in the use of Zyesami.

NRx said over 1,000 new cases of Covid-19 are being diagnosed in Georgia each day, and there has also been increasing detection of the Delta variant.

At 11:58 p.m. EDT, the company's shares were trading 14.07% higher at $21.32. Volume at the time topped 10.7 million shares, above the stock's 65-day average volume of some 3.2 million.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

July 27, 2021 12:27 ET (16:27 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more NRX Pharmaceuticals Charts.
NRX Pharmaceuticals (NASDAQ:NRXP)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more NRX Pharmaceuticals Charts.